皓宸医疗科技股份有限公司主要从事口腔医疗服务以及永磁开关及高低压开关成套设备产品的研发、生 产和销售。其主要产品有医疗口腔服务、实业开关产品、征信大数据软件服务。 4月9日，皓宸医疗今日收盘2.45元，上涨2.08%，最新市净率4.60，总市值20.58亿元。 资金流向方面，4月9日，皓宸医疗主力资金净流入106.30万元，近5日总体呈流出状态，5日共流出 774.66万元。 最新一期业绩显示，2024年三季报，公司实现营业收入6.35亿元，同比21.27%；净利润1349.67万元， 同比-17.31%，销售毛利率47.97%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)9皓宸医疗-21.18-21.814.6020.58亿行业平均 45.7741.333.33140.72亿行业中值43.7835.472.4544.48亿1普瑞眼科-192.3424.042.9064.41亿2何氏眼 科-144.5344.311.4628.16亿3迪安诊断-92.5027.851.2185.62亿4光正眼科-84.88201.676.8418.66亿5创新医 疗-78.10-109.142.0337.42亿6南 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)9皓宸医疗-21.61-22.254.6921.00亿行业平均 45.7240.943.28142.68亿行业中值41.8333.882.5543.24亿1普瑞眼科-173.2621.662.6258.02亿2何氏眼 科-136.5041.851.3726.60亿3光正眼科-86.53205.596.9719.03亿4迪安诊断-85.2825.671.1278.93亿5南华生 物-80.12-105.4311.9529.70亿6创新医疗-78.19-109.272.0337.47亿7国际医学-31.81-30.933.12113.92亿8嘉和 美康-25.49-25.492.1438.24亿10美迪西-11.36-11.361.5335.89亿11和元生物-10.03-10.031.7432.58亿 来源：金融界 皓宸医疗科技股份有限公司主要从事口腔医疗服务以及永磁开关及高低压开关成套设备产品的研发、生 产和销售。其主要产品有医疗口腔服务、实业开关产品、征信大数据软件服务。 最新一期业绩显示，2024年三季报，公司实现营业收入6.35亿元，同比21.27% ...

3月28日，皓宸医疗今日收盘2.82元，下跌2.42%，最新市净率5.29，总市值23.69亿元。 资金流向方面，3月28日，皓宸医疗主力资金净流入18.76万元，近5日总体呈流出状态，5日共流出 457.04万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10皓宸医疗-24.37-25.105.2923.69亿行业平均 48.4142.073.76164.84亿行业中值43.5638.122.8453.46亿1昭衍新药-17438.3340.101.99159.19亿2普瑞眼 科-183.4522.932.7761.43亿3何氏眼科-162.3049.761.6331.62亿4迪安诊断-107.2232.281.4199.25亿5光正眼 科-95.02225.767.6620.89亿6南华生物-86.27-113.5112.8631.98亿7创新医疗-84.17-117.632.1940.33亿8国际 医学-35.09-34.123.44125.68亿9嘉和美康-30.24-30.242.5445.35亿11美迪西-14.01-14.011.8844.27亿 来源：金融界 皓宸医疗科技股份有限 ...

Revenue Projections - The estimated revenue for 2024 is projected to be between 800 million and 900 million CNY, compared to 756.71 million CNY in the same period last year, indicating a growth of approximately 5.7% to 18.8%[3] Profit and Loss Expectations - The net profit attributable to shareholders is expected to be a loss of between 40 million and 22 million CNY, an improvement from a loss of 94.37 million CNY in the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 20 million and 11 million CNY, compared to a loss of 85.10 million CNY last year, showing a significant reduction in losses[3] - The basic earnings per share is expected to be a loss of between 0.0476 CNY and 0.0262 CNY, improving from a loss of 0.1123 CNY per share in the previous year[3] Operational Performance - The company has seen continuous growth in revenue from oral medical services and permanent magnet switch business, contributing to overall operational quality improvement[5] Investment Income and Risk Management - The decline in investment income is attributed to the impairment provisions made by the company's associate, Fushun Bank, to enhance risk resistance capabilities[5] - The company plans to recognize overdue interest based on prudence due to ongoing litigation matters, contributing to the overall expected loss for 2024[5] Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed financial information to be disclosed in the 2024 annual report[7]

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-042 特此公告。 皓宸医疗科技股份有限公司董事会 二〇二四年十二月三十日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开第 五届董事会第十一次会议、第五届监事会第十一次会议，审议通过了《关于德伦 医疗 2023 年度业绩补偿方案的议案》，公司以现金方式购买的广东德伦医疗集团 有限公司（以下简称"德伦医疗"）51.00%股权，因德伦医疗未能完成 2023 年度 业绩承诺，业绩承诺方须按照约定履行补偿义务。 根据众华会计师事务所（特殊普通合伙）针对德伦医疗 2023 年度业绩完成情 况出具的《皓宸医疗科技股份有限公司实际盈利数与利润预测数差异情况专项审 核报告》（众会字（2024）第 03479 号），德伦医疗 2023 年度业绩实际数为 7,394.57 万元。截至 2023 年末德伦医疗累计实现业绩数为 5,593.51 万元，累计承诺业绩 金额 15,500.00 万元，扣除 2022 年度已补偿金额后的差额为 ...

表决结果：通过。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届监事会第十三次会 议于 2024 年 10 月 18 日以电子邮件的形式发出会议通知，会议于 2024 年 10 月 30 日上午 11:00 在公司会议室以现场结合通讯表决方式召开。会议应参加表决 监事 3 人，实际参加表决监事 3 人。会议由监事会主席刘月先生召集并主持，会 议的内容以及召集、召开的方式、程序均符合《中华人民共和国公司法》和《公 司章程》的规定。 经与会监事认真审议并表决，通过了以下议案： 一、审议通过《关于 2024 年第三季度报告的议案》 表决情况：同意 3 票，反对 0 票，弃权 0 票； 证券代码：002622 证券简称：皓宸医疗 公告编号：2024-040 皓宸医疗科技股份有限公司 第五届监事会第十三次会议决议公告 特此公告。 皓宸医疗科技股份有限公司监事会 二〇二四年十月三十日 经审核，监事会认为董事会编制和审核《皓宸医疗科技股份有限公司 2024 年第三季度报告》的程序符合法律、行政法规及中国证监会和深圳证券交易 ...

Financial Performance - Revenue for Q3 2024 reached ¥253,020,064.77, an increase of 20.48% year-over-year[2] - Net profit attributable to shareholders was ¥12,943,174.20, up 48.76% compared to the same period last year[2] - Net profit after deducting non-recurring gains and losses was ¥12,822,455.55, reflecting a 52.13% increase year-over-year[2] - Total operating revenue for Q3 2024 reached ¥635,030,298.87, an increase of 21.3% compared to ¥523,639,966.97 in the same period last year[20] - Operating profit for Q3 2024 was ¥31,450,295.28, down 8.0% from ¥34,527,160.94 in Q3 2023[21] - Net profit attributable to shareholders of the parent company was ¥13,496,659.38, a decrease of 17.4% from ¥16,321,536.90 in the previous year[22] - The company reported a decrease in comprehensive income attributable to shareholders of the parent company to ¥30,221,773.21 from ¥37,234,881.52 in the previous year[22] - Basic earnings per share for Q3 2024 were ¥0.0161, compared to ¥0.0194 in Q3 2023[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,565,747,164.97, representing a 1.94% increase from the end of the previous year[2] - The total assets of the company as of the latest report amount to CNY 1,565,747,164.97, an increase from CNY 1,535,890,599.57 at the beginning of the period[18] - The company's current liabilities total CNY 893,347,731.93, slightly up from CNY 891,757,164.96 at the beginning of the period[18] - Total liabilities increased to ¥1,073,322,431.77 from ¥1,070,747,639.58 year-over-year[19] - Shareholders' equity attributable to the parent company increased to ¥447,820,785.37, a rise of 3.47% compared to the end of last year[2] - The company’s total equity increased to ¥492,424,733.20, compared to ¥465,142,959.99 in Q3 2023[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥43,066,291.87, down 5.89% compared to the previous year[2] - The company reported a net cash flow from operating activities of ¥43,066,291.87, slightly down from ¥45,761,050.12 in Q3 2023[23] - Net cash flow from investment activities was -7,246,655.63, a decrease from 8,465,505.96 in the previous period[24] - Cash inflow from financing activities amounted to 78,400,000.00, significantly up from 17,000,000.00 in the prior period[24] - Cash outflow from financing activities totaled 103,754,320.53, compared to 39,356,135.12 previously[24] - The net cash flow from financing activities was -25,354,320.53, slightly worse than -22,356,135.12 in the last period[24] - The ending balance of cash and cash equivalents was 152,382,007.24, up from 150,098,941.99 at the end of the previous period[24] - The net increase in cash and cash equivalents for the quarter was 10,465,350.70, down from 31,870,420.96 in the previous quarter[24] Research and Development - R&D expenses decreased by ¥5,090,000, a reduction of 47.70% year-over-year[5] - Research and development expenses for Q3 2024 were ¥5,583,042.65, down from ¥10,675,860.37 in the same period last year[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 44,932[8] - The largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, holds 23.81% of the shares[8] - The second-largest shareholder, Shaanxi International Trust Co., holds 3.84% of the shares[8] Legal and Regulatory Issues - The company has disclosed multiple legal proceedings related to asset management disputes, with updates provided on various dates throughout 2024[10] - The company has reported that some bank accounts have been frozen, with ongoing updates on the situation[12] - The company is actively communicating with the Shanghai Financial Court regarding the execution procedures related to a legal case[11] - The company is facing uncertainty regarding control changes, as a lawsuit has been filed against it, and the outcome is pending[16] Asset Management and Freezing Issues - The company’s assets have been frozen due to a loan dispute, with the equity of its wholly-owned subsidiary, Zhiyu Medical, frozen for an amount of CNY 50 million, lasting for 1,097 days[14] - The total frozen bank balance of the company and its subsidiaries is CNY 574,164.23, accounting for 0.13% of the latest audited net assets[14] - The company is actively negotiating with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank to resolve the asset and account freezing issues through extension, installment repayment, and financing replacement[14] - The company’s largest shareholder, Huayin Rifen, has sent a notice indicating that the Shanghai Pudong Development Bank Guangzhou Branch has become the sole trustee of a specific asset management plan[15] Investment Risks - The company emphasizes the importance of investors being aware of investment risks[11] Audit Status - The company has not undergone an audit for the third quarter report[24]

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-039 《2024 年第三季度报告》详见公司指定信息披露媒体《中国证券报》、《上 海证券报》、《证券时报》及巨潮资讯网（www.cninfo.com.cn）2024 年 10 月 31 日公告。 皓宸医疗科技股份有限公司 二、备查文件 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十三次会 议于2024年10月30日上午10:00在公司会议室以现场结合通讯表决方式召开。 召开本次会议的通知已于 2024 年 10 月 18 日以电话、电子邮件等方式通知了各 位董事，会议应参加表决董事 7 名，实际参加表决董事 7 名。此次会议的召集、 召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法律、法 规的规定，合法有效。 一、审议通过《关于 2024 年第三季度报告的议案》 经与会董事认真审议并表决，通过了以下议案： 表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 1、《皓宸 ...

一、股票交易异常波动情况 皓宸医疗科技股份有限公司（以下称"公司"或"本公司"）股票（证券简 称：皓宸医疗，证券代码：002622）交易价格连续 3 个交易日（2024 年 10 月 22 日至 2024 年 10 月 24 日）收盘价格涨幅偏离值累计超过 20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票交易异常波动的情形。 二、公司关注、核实情况的说明 针对公司股票异常波动，公司对有关事项进行了核查，并询问了公司第一大 股东，现将相关情况说明如下： 1、截至本公告日，公司前期披露的信息不存在需要更正、补充之处； 皓宸医疗科技股份有限公司 证券代码：002622 证券简称：皓宸医疗 公告编号：2024-038 股票交易异常波动公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 三、是否存在应披露而未披露的信息的声明 经公司董事会确认，除前述情况外，公司目前没有任何根据深交所《股票上 市规则》等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、 意向、协议等；董事会也未获悉本公司有根据深交所《股票上市规则》等有关规 定应予以披露而未披露的、对 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2024-037 皓宸医疗科技股份有限公司关于第一大股东 执行事务合伙人收到《民事上诉状》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于近日收到第一大股东广州 汇垠日丰投资合伙企业（有限合伙）（以下简称"汇垠日丰"）发来的《民事上诉状》。 北京首拓融汇投资有限公司（以下简称"北京首拓融汇"）因关于请求确认公司第 一大股东汇垠日丰执行事务合伙人广州汇垠澳丰股权投资基金管理有限公司（以 下简称"汇垠澳丰"）于 2023 年 8 月 4 日向北京首拓融汇发出的《关于解除<合作 协议>的函》无效一案，不服广州市南沙区人民法院出具的（2023）粤 0115 民初 10080 号民事判决，已向广州市中级人民法院提起上诉，现将相关事项公告如下： 一、本次诉讼的基本情况 公司分别于 2023 年 7 月 5 日、2023 年 8 月 9 日、2023 年 8 月 22 日在巨潮资 讯网披露了《关于公司控制权可能发生变更的提示性公告》（公告编号：2023-026）、 《 ...